Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

1.

Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy.

Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N.

Intervirology. 2014 Jun 28;57(5):289-296. [Epub ahead of print]

PMID:
24992890
[PubMed - as supplied by publisher]
2.

Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.

Hepatol Res. 2014 May 22. doi: 10.1111/hepr.12360. [Epub ahead of print]

PMID:
24849518
[PubMed - as supplied by publisher]
3.

A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.

Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M.

Hepatol Res. 2014 Mar 10. doi: 10.1111/hepr.12323. [Epub ahead of print]

PMID:
24606109
[PubMed - as supplied by publisher]
4.

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E.

Hepatology. 2014 Jun;59(6):2083-91. doi: 10.1002/hep.27113. Epub 2014 Apr 1.

PMID:
24604476
[PubMed - indexed for MEDLINE]
5.

Changes in hepatitis C virus genotype distribution in Japan.

Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J.

Epidemiol Infect. 2014 Mar 5:1-5. [Epub ahead of print]

PMID:
24598252
[PubMed - as supplied by publisher]
6.

Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor.

Moritou Y, Ikeda F, Iwasaki Y, Baba N, Takaguchi K, Senoh T, Nagano T, Takeuchi Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K.

Acta Med Okayama. 2014;68(1):17-22.

PMID:
24553484
[PubMed - in process]
Free Article
7.

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.

J Gastroenterol. 2013 Nov 28. [Epub ahead of print]

PMID:
24287582
[PubMed - as supplied by publisher]
8.

Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.

Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group.

Br J Cancer. 2013 Oct 15;109(8):2072-8. doi: 10.1038/bjc.2013.554. Epub 2013 Sep 17.

PMID:
24045661
[PubMed - indexed for MEDLINE]
9.

Usefulness of combined application of double-filtration plasmapheresis and twice-daily injections of interferon-╬▓ in hemodialysis patients with hepatitis C virus genotype 1b infection and a high viral load.

Zeniya M, Nakano M, Saeki C, Yokoyama K, Ishikawa T, Takaguchi K, Takahashi H.

Hepatol Res. 2013 Jul 16. doi: 10.1111/hepr.12207. [Epub ahead of print]

PMID:
23855529
[PubMed - as supplied by publisher]
10.

Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C.

Moritou Y, Ikeda F, Iwasaki Y, Baba N, Takaguchi K, Senoh T, Nagano T, Takeuchi Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K.

Springerplus. 2013 Jun 1;2(1):251. Print 2013 Dec.

PMID:
23772356
[PubMed]
Free PMC Article
11.

Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.

Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Iwadou S, Kobayashi Y, Takaguchi K, Takuma Y, Takabatake H, Sakaguchi K, Yamamoto K; Okayama Liver Cancer Group.

Hepatol Res. 2014 Mar;44(3):296-301. doi: 10.1111/hepr.12123. Epub 2013 Apr 29.

PMID:
23607549
[PubMed]
12.

Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial.

Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, Okita K; ASCITES-DOUBLEBLIND Study Group.

Hepatol Res. 2014 Jan;44(1):73-82. doi: 10.1111/hepr.12098. Epub 2013 Apr 3.

PMID:
23551935
[PubMed]
13.

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.

Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N.

BMC Infect Dis. 2012 Nov 27;12:324. doi: 10.1186/1471-2334-12-324.

PMID:
23181537
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.

Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N.

J Med Virol. 2013 Jan;85(1):65-70. doi: 10.1002/jmv.23428.

PMID:
23154876
[PubMed - indexed for MEDLINE]
15.

Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis.

Takaguchi K, Moriwaki H, Doyama H, Iida M, Yagura M, Shimada N, Kang M, Yamada H, Kumada H.

Hepatol Res. 2013 May;43(5):459-66. doi: 10.1111/j.1872-034X.2012.01097.x. Epub 2012 Oct 10.

PMID:
23046471
[PubMed]
Free PMC Article
16.

Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.

Ikeda F, Baba N, Takaguchi K, Kubota J, Miyoshi K, Fujioka S, Moritou Y, Takeuchi Y, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K.

J Med Virol. 2012 Oct;84(10):1562-70. doi: 10.1002/jmv.23371.

PMID:
22930504
[PubMed - indexed for MEDLINE]
17.

Inhibition of hepatocellular carcinoma by PegIFN╬▒-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.

Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, Kumada H.

J Gastroenterol. 2013 Mar;48(3):382-90. doi: 10.1007/s00535-012-0641-9. Epub 2012 Aug 9.

PMID:
22875473
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].

Wato M, Inaba T, Ishikawa H, Ishikawa S, Baba N, Miyoshi M, Senoh T, Nagano T, Takaguchi K, Watanabe S, Kawai K.

Nihon Shokakibyo Gakkai Zasshi. 2010 Oct;107(10):1676-85. Review. Japanese.

PMID:
20938119
[PubMed - indexed for MEDLINE]
19.

Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.

Kaneko S, Sata M, Ide T, Yamashita T, Hige S, Tomita E, Mochida S, Yamashita Y, Inui Y, Kim SR, Komada N, Mikami T, Satoh S, Morita S, Takaguchi K, Hirashima N, Nishio Y, Watanabe D, Kioka K, Fujiwara K.

Hepatol Res. 2010 Nov;40(11):1072-81. doi: 10.1111/j.1872-034X.2010.00708.x. Epub 2010 Sep 28.

PMID:
20880058
[PubMed]
20.

Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.

Iwasaki Y, Tanaka H, Ikeada H, Okamoto R, Araki Y, Yabushita K, Kobashi H, Kariyama K, Kawaguchi M, Takaguchi K, Sakata T, Ando M, Sakaguchi K, Aoki N, Shiratori Y.

Scand J Gastroenterol. 2011 Jan;46(1):79-90. doi: 10.3109/00365521.2010.516449. Epub 2010 Sep 7.

PMID:
20822376
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk